ArticleSkin health and disease2025
Fully ablative CO
Article in Skin health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Rhinophyma: a systematic review and meta-analysis of its epidemiology, associations, and treatment outcomes.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Pooled it
- Recurrent Rhinophyma: A Case of Triple Relapse and Therapeutic Challenges.Clinical case reports · 2026Article
- COClinical, cosmetic and investigational dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rhinophyma, a progressive nasal deformity resulting from advanced rosacea, presents significant cosmetic and functional challenges. Fully ablative CO Objectives: To assess the long-term outcomes, safety and patient satisfaction associated with fully ablative CO Methods: A retrospective study was conducted on 152 patients with rhinophyma (grades I-III) treated with CO Results: Significant aesthetic improvement (GAIS ≥ 3) was observed in 84% of p atients, with an average satisfaction score of 2.51/3. Recurrence was rare (4%), occurring primarily in older men with grade III rhinophyma. Side effects included mild hypopigmentation (9%) and textural changes (2%). A deep learning model identified rhinophyma grade, age and Fitzpatrick phototype as key predictors of treatment outcomes. Logistic regression confirmed that advanced rhinophyma grades significantly reduced hypopigmentation risk [adjusted odds ratio (aOR) 0.43, 95% confidence interval (CI) 0.18-0.97; Conclusions: Fully ablative CO
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.